

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ulrich Laemmli  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
For : MODULATION OF CHROMOSOME FUNCTION BY  
CHROMATIN REMODELING AGENTS

1185 Avenue of the Americas  
New York, New York 10036  
June 26, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Applicants request that the following amendments be made in the  
above-identified application.

In the Specification

Page 1, after the title please insert the following paragraph:

--This application claims priority of U.S. Provisional  
Application No. 60/213,931, filed June 26, 2000, the  
contents of which are hereby incorporated by reference  
into the present disclosure.--

Ulrich Laemmli  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 2

In the Claims:

Please cancel claims 40-76 without prejudice to applicants' right to pursue the subject matter of these claims in a subsequent application.

Please amend claims 9, 11, 15, 16, 20 and 21. The text of the claims as amended follows:

--9.(amended) Process according to claim 1, wherein the CRE is cis-acting with respect to said other DNA element(s), in either a local or long-range manner.--

--11.(amended) Process according to claim 1 wherein the CRE is trans-acting in that the other DNA element(s) is or are not directly linked to the CRE.--

--15.(amended) Process according to claim 1 wherein the other DNA element(s) is (are) endogenous to said cell.--

--16.(amended) Process according to claim 1 wherein the other DNA element(s) is (are) heterologous to said cell.--

--20.(amended) Process according to claim 1 wherein the sequence-specific DNA binding compound binds to the DNA minor groove.--

Ulrich Laemmli  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 3

--21.(amended) Process according to claim 1 wherein the sequence-specific DNA binding compound is cell-permeable.--

#### REMARKS

The subject application claims the priority of U.S. Provisional Application No. 60/213,931, filed June 26, 2000.

By this Amendment, applicants have canceled claims 40-76 without prejudice to applicants' right to pursue the subject matter of these claims in a subsequent application and amended claims 9, 11, 15, 16, 20 and 21. Accordingly, claims 1-39 are currently pending and under examination.

Applicants maintain that amended claims 1-39 raise no issue of new matter. Accordingly, applicants respectfully request that the Amendment be entered. An annotated version of amended claims showing all changes relative to the previous version of that claim is attached hereto as **Exhibit A**.

Applicants have added the paragraph recited hereinabove to update the continuing data of the present application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

Ulrich Laemmli  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 4

No fee, other than the enclosed fee of \$715.00 for filing the subject application, is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such additional fee to Deposit Account No. 03-3125.

Respectfully submitted,



---

John P. White  
Registration No. 28,678  
Jane M. Love  
Registration No. 42,812  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

**Exhibit A - An annotated version of amended claims showing all changes relative to the previous version of that claim:**

- 9.(amended) Process according to claim 1, [2 or 3] wherein the CRE is cis-acting with respect to said other DNA element(s), in either a local or long-range manner.--
- 11.(amended) Process according to [any one of claims] claim 1 [to 4] wherein the CRE is trans-acting in that the other DNA element(s) is or are not directly linked to the CRE.--
- 15.(amended) Process according to [any one of claims] claim 1 [to 14] wherein the other DNA element(s) is (are) endogenous to said cell.--
- 16.(amended) Process according to [any one of claims] claim 1 [to 14] wherein the other DNA element(s) is (are) heterologous to said cell.--
- 20.(amended) Process according to [any one of claims] claim 1 [to 19,] wherein the sequence-specific DNA binding compound binds to the DNA minor groove.--
- 21.(amended) Process according to [any one of claims] claim 1 [to 20] wherein the sequence-specific DNA binding compound is cell-permeable.--